Side-by-side · Research reference

TestagenvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/41 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Testagen

Bioregulator Peptide · Khavinson School

Lys-Glu-Asp-GlySequenceFedoreyeva 2011

NuclearLocalizationFedoreyeva 2011

TesticularTissue target

SQ · Abdomen · Cyclical

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Testagen

VIP

Primary target

Testicular tissue; proposed nuclear DNA interaction

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Nuclear penetration → DNA/oligonucleotide binding → gene expression modulation (bioregulator hypothesis)Fedoreyeva 2011

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Proposed support for spermatogenesis and testicular function; mechanistic data limited to nuclear localization and DNA interactionFedoreyeva 2011

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

Unknown — no HPG axis data

Yes — exogenous VIP acts as physiological agonist

Origin

Khavinson bioregulator school — isolated from testicular tissue peptide fractions

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Testagen

VIP

Typical protocol (anecdotal)

100–200 mcg / day

No published human dosing studies; derived from Russian bioregulator practice.

—

Frequency

Once daily or alternate days

—

Cycle length

10–20 days on, 10–14 days off

Bioregulator tradition uses pulsed cycles; no controlled data.

—

Evidence basis

Animal mechanistic / in vitro onlyFedoreyeva 2011

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Route

Subcutaneous

—

Reconstitution

Sterile water or bacteriostatic saline

Lyophilized powder reconstituted with sterile diluent per protocol

Half-life

Unknown — likely minutes (short peptide)

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

04Side Effects & Safety

Parameter

Testagen

VIP

Injection site reactions

Erythema, mild irritation (potential)

—

Systemic effects

Unknown — no human safety data

—

Hormonal impact

No published data on testosterone, LH, FSH effects

—

Long-term safety

Unknown — no long-term studies

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Testagen

·Active testicular malignancy

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Testagen

·Hormone-sensitive cancers (no data; theoretical caution)
·Pregnant or breastfeeding (no data)

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Testagen

VIP

1. Reconstitution

Add 1–2 mL sterile or bacteriostatic water to lyophilised vial. Swirl gently; do not shake. Solution should be clear.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites daily. Use standard insulin syringe (27–31G).

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Morning or evening; no established optimal timing. Anecdotal preference: evening to align with circadian testosterone patterns.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: room temp, dark. Reconstituted: refrigerate 2–8 °C, use within 14–21 days if bacteriostatic water used.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Cycle protocol

10–20 days on, 10–14 days off. Bioregulator tradition uses pulsed exposure; rationale: prevent receptor/pathway desensitisation.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.